FDA okays Onyx AVM (arteriovenous malformations) trial:
This article was originally published in Clinica
Executive Summary
The US FDA has given Micro Therapeutics (MTI) the green-light to begin a 106-patient, pivotal trial of its Onyx liquid embolic system for the treatment of arteriovenous malformations (AVMs). The Irvine, California firm has already started a pivotal US trial of the product for the treatment of brain aneurysms.